590417-93-9

Usage

Uses

Used in Chemical Synthesis:
4-Bromo-2-Methyl-2H-Indazole is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows for the creation of a wide range of molecules with potential applications in different industries.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Bromo-2-Methyl-2H-Indazole is used as a building block for the development of new pharmaceutical compounds. Its chemical properties make it a valuable component in the synthesis of potential drug candidates, particularly those targeting specific biological receptors or enzymes.
Used in Material Science:
4-Bromo-2-Methyl-2H-Indazole may also find applications in material science, where its aromatic and heterocyclic nature could contribute to the development of novel materials with unique electronic, optical, or mechanical properties.

InChI:InChI=1/C8H7BrN2/c1-11-5-6-7(9)3-2-4-8(6)10-11/h2-5H,1H3

Upstream product

• 74-88-4 methyl iodide 
• 186407-74-9 4-bromoindazole 
• 420-37-1 trimethoxonium tetrafluoroborate 

Downstream Products

• 885698-95-3 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole 

Relevant academic research and scientific papers

METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS

Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

New hypotheses for the binding mode of 4- and 7-substituted indazoles in the active site of neuronal nitric oxide synthase

Taking into account the potency of 4- and 7-nitro and haloindazoles as nNOS inhibitors previously reported in the literature by our team, a multidisciplinary study, described in this article, has recently been carried out to elucidate their binding mode in the enzyme active site. Firstly, nitrogenous fastening points on the indazole building block have been investigated referring to molecular modeling hypotheses and thanks to the in vitro biological evaluation of N1- and N2-methyl and ethyl-4-substituted indazoles on nNOS. Secondly, we attempted to confirm the importance of the substitution in position 4 or 7 by a hydrogen bond acceptor group thanks to the synthesis and the in vitro biological evaluation of a new analogous 4-substituted derivative, the 4-cyanoindazole. Finally, by opposition to previous hypotheses describing NH function in position 1 of the indazole as a key fastening point, the present work speaks in favour of a crucial role of nitrogen in position 2.

BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s); R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); Xa and Xb are each C, N, O or S; Xc and Xd are each C or N; m is 0-2; n is 1-3; ring A is a 5-membered ring optionally having substituent(s); ring B is a 6-membered ring optionally having substituent(s); and ring C is a 3- to 5-membered ring optionally having substituent(s), provided that when Xa, Xc and Xd are each C, then Xb is N or S, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.